Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 365.12% from the company’s current price.

GANX has been the subject of a number of other reports. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Wednesday, August 14th.

Gain Therapeutics Price Performance

NASDAQ:GANX opened at $1.72 on Monday. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $5.33. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average is $2.06 and its two-hundred day moving average is $1.72. The company has a market capitalization of $45.61 million, a P/E ratio of -1.56 and a beta of 0.33.

Institutional Trading of Gain Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GANX. Hohimer Wealth Management LLC purchased a new stake in shares of Gain Therapeutics in the 2nd quarter valued at about $422,000. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics in the 2nd quarter valued at about $66,000. Renaissance Technologies LLC lifted its holdings in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after purchasing an additional 72,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the last quarter. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.